{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:20:03Z","timestamp":1789564803237,"version":"build-2803163510"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","funder":[{"name":"Food and Drug Administration"},{"DOI":"10.13039\/100001296","name":"PKD Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"US Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Critical Path Institute"},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.2215\/cjn.05190422","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T16:05:13Z","timestamp":1661270713000},"page":"1555-1558","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Perspectives on Drug Development in Early ADPKD"],"prefix":"10.2215","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct02964273","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0954-6088","authenticated-orcid":false,"given":"Djalila","family":"Mekahli","sequence":"first","affiliation":[{"name":"Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Polycystic Kidney Disease Research Group, Department of Development and Regeneration, Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-2771","authenticated-orcid":false,"given":"Hayley","family":"Womack","sequence":"additional","affiliation":[{"name":"Kansas City University College of Osteopathic Medicine, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-9961","authenticated-orcid":false,"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: Core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B2-20241015","first-page":"EVIDoa2100021","article-title":"Prescribed water intake in autosomal dominant polycystic kidney disease","volume":"1","author":"Rangan","year":"2021","journal-title":"NEJM Evid"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.kint.2020.03.023","article-title":"Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: Efficacy, safety, and tolerability","volume":"98","author":"Meijer","year":"2020","journal-title":"Kidney Int"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00467-021-04974-4","article-title":"The wind of change in the management of autosomal dominant polycystic kidney disease in childhood","volume":"37","author":"Gimpel","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.ajkd.2018.11.001","article-title":"Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","volume":"73","author":"Smith","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1053\/j.ajkd.2017.10.023","article-title":"Patterns of kidney function decline in autosomal dominant polycystic kidney disease: A post hoc analysis from the HALT-PKD trials","volume":"71","author":"Brosnahan","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2215\/CJN.10470620","article-title":"Use of the urine-to-plasma urea ratio to predict ADPKD progression","volume":"16","author":"Heida","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2050640617705577","article-title":"Impact of liver volume on polycystic liver disease-related symptoms and quality of life","volume":"6","author":"Neijenhuis","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/j.ajkd.2020.01.005","article-title":"Core outcome domains for trials in autosomal dominant polycystic kidney disease: An international Delphi survey","volume":"76","author":"Cho","year":"2020","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.05190422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:55Z","timestamp":1786369495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.05190422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.05190422","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}